GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Cyclically Adjusted PB Ratio

NeoGenomics (NeoGenomics) Cyclically Adjusted PB Ratio : 2.48 (As of Jun. 08, 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Cyclically Adjusted PB Ratio?

As of today (2024-06-08), NeoGenomics's current share price is $13.01. NeoGenomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $5.24. NeoGenomics's Cyclically Adjusted PB Ratio for today is 2.48.

The historical rank and industry rank for NeoGenomics's Cyclically Adjusted PB Ratio or its related term are showing as below:

NEO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.63   Med: 16.75   Max: 49.88
Current: 2.48

During the past years, NeoGenomics's highest Cyclically Adjusted PB Ratio was 49.88. The lowest was 1.63. And the median was 16.75.

NEO's Cyclically Adjusted PB Ratio is ranked worse than
61.03% of 136 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.01 vs NEO: 2.48

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeoGenomics's adjusted book value per share data for the three months ended in Mar. 2024 was $7.246. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $5.24 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NeoGenomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Cyclically Adjusted PB Ratio Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.00 25.36 10.85 2.23 3.24

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.96 3.48 2.54 3.24 3.00

Competitive Comparison of NeoGenomics's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PB Ratio falls into.



NeoGenomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NeoGenomics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=13.01/5.24
=2.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, NeoGenomics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.246/131.7762*131.7762
=7.246

Current CPI (Mar. 2024) = 131.7762.

NeoGenomics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.463 100.560 0.607
201409 0.985 100.428 1.292
201412 1.003 99.070 1.334
201503 0.997 99.621 1.319
201506 1.006 100.684 1.317
201509 1.021 100.392 1.340
201512 2.763 99.792 3.649
201603 2.674 100.470 3.507
201606 2.615 101.688 3.389
201609 2.558 101.861 3.309
201612 2.084 101.863 2.696
201703 2.128 102.862 2.726
201706 2.129 103.349 2.715
201709 2.110 104.136 2.670
201712 2.137 104.011 2.707
201803 2.142 105.290 2.681
201806 2.012 106.317 2.494
201809 3.265 106.507 4.040
201812 3.392 105.998 4.217
201903 3.398 107.251 4.175
201906 4.717 108.070 5.752
201909 4.772 108.329 5.805
201912 4.843 108.420 5.886
202003 4.792 108.902 5.799
202006 5.926 108.767 7.180
202009 6.003 109.815 7.204
202012 6.195 109.897 7.428
202103 7.203 111.754 8.493
202106 9.358 114.631 10.758
202109 9.230 115.734 10.509
202112 8.930 117.630 10.004
202203 8.619 121.301 9.363
202206 8.303 125.017 8.752
202209 8.004 125.227 8.423
202212 7.864 125.222 8.276
202303 7.661 127.348 7.927
202306 7.521 128.729 7.699
202309 7.445 129.860 7.555
202312 7.392 129.419 7.527
202403 7.246 131.776 7.246

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeoGenomics  (NAS:NEO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NeoGenomics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913